Zynex, Inc. (NASDAQ: ZYXI) is a prominent player in the medical technology sector, specializing in non-invasive devices for pain management and rehabilitation. Based in Englewood, Colorado, Zynex is navigating a transformative phase under new management since August 2025. The company is focused on overcoming business challenges and enhancing its financial health.

On November 17, 2025, Zynex reported its earnings, revealing an EPS of -$1.42, which was significantly below the expected -$0.19. The company's revenue also fell short, coming in at $13.36 million against an estimated $24.53 million. This performance reflects ongoing financial difficulties, as highlighted by a negative P/E ratio of -0.23.

Zynex's management, led by CEO Steven Dyson, is committed to addressing these challenges. They are implementing a three-part strategy to improve compliance, liquidity, and revenue. Despite the third quarter's performance mirroring earlier results, Dyson emphasizes progress in strategic initiatives aimed at rebuilding the company's strength.

The company's financial metrics further illustrate its current struggles. With a price-to-sales ratio of 0.16 and an enterprise value to sales ratio of 0.70, the market values Zynex's sales and revenue at relatively low levels. Additionally, the enterprise value to operating cash flow ratio of -3.67 indicates difficulties in generating positive cash flow.

Zynex's financial health is further challenged by a negative earnings yield of -4.32% and a debt-to-equity ratio of -1.73, suggesting more liabilities than equity. The current ratio of 0.47 points to potential liquidity issues, as it falls below the standard threshold of 1, indicating the company may struggle to meet short-term obligations.